Autosomal trisomy of group G represents a fundamental milestone in human cytogenetics, designating the presence of a supernumerary small acrocentric autosome belonging to Denver Group G (chromosomes 21 and 22). First identified as the chromosomal etiology of Down syndrome by Jérôme Lejeune and colleagues in 1959, this genomic aberration fundamentally reshaped modern medical genetics, reproductive endocrinology, and developmental biology. Understanding the mechanisms of nondisjunction, aneuploidy, and gene-dosage imbalance associated with Group G autosomes provides essential insights into phenotypic variation, intellectual disability, congenital organ malformations, and cellular homeostasis.
1. Concise Definition
Autosomal trisomy of group G is a constitutional chromosomal abnormality characterized by the presence of an extra (third) copy of one of the small acrocentric autosomes categorized under Group G of the Denver Classification System, specifically chromosome 21 or chromosome 22. In clinical and cytogenetic nomenclature, this condition arises when an individual possesses 47 chromosomes instead of the standard diploid complement of 46, designated typically as 47,XX,+G or 47,XY,+G.
While Group G encompasses both autosomes 21 and 22, the vast majority of viable clinical cases involve trisomy 21 (the cytogenetic basis of Down syndrome), representing the most prevalent viable autosomal aneuploidy in humans. Conversely, complete trisomy 22 represents a severe, frequently lethal anomaly that accounts for a notable percentage of early spontaneous miscarriages, surviving to term only in rare instances characterized by somatic mosaicism or partial translocation aneuploidy. The condition leads to systemic alterations in gene dosage, embryonic patterning, metabolic pathways, and cellular stress responses across multiple organ systems.
2. Etymology & Linguistic Origin
The term autosomal trisomy of group G derives from classical Greek morphological roots integrated into twentieth-century medical and cytogenetic terminology. The word autosomal stems from the Greek autos (meaning "self" or "same") combined with soma (meaning "body"), reflecting chromosomes that are identical in both biological sexes, distinguishing them from the allosomes or sex chromosomes. The term trisomy originates from the Greek tri- (meaning "three") and soma ("body"), coined in early botanical and insect genetics to denote the abnormal presence of three homologous chromosomes instead of a pair.
The classification designation Group G arose directly from the historical Denver Conference of 1960, wherein human geneticists convened to standardize the karyotypic arrangement of human chromosomes based on physical length and centromere positioning. The Latin alphabet letters A through G were assigned to distinct morphological clusters; Group G was designated to encompass the shortest acrocentric chromosomes (pairs 21 and 22, along with the Y chromosome). Historically, before the invention of high-resolution fluorescent and Giemsa banding techniques, researchers could not reliably differentiate chromosome 21 from chromosome 22 beneath light microscopy, necessitating the collective phenotypic and cytogenetic label "Group G trisomy."
3. Pronunciation & Grammatical Form
In standard medical and academic English, the phrase is pronounced phonetically as /ɔːtəˈsoʊməl traɪˈsoʊmi əv ɡruːp dʒiː/. Grammatically, the term functions as a complex nominal phrase. "Autosomal" serves as a classifying adjective modifying the noun "trisomy," which is further specified by the prepositional phrase "of group G."
In formal cytogenetic reporting following the International System for Human Cytogenomic Nomenclature (ISCN), the grammatical form transitions into standardized alphanumeric expressions. Historically documented as 47,XX,+G or 47,XY,+G, modernized nomenclature specifies the exact chromosome involved, appearing as 47,XX,+21 or 47,XY,+22. The noun can appear in plural form as "autosomal trisomies of group G" when discussing the comparative epidemiology, cellular mechanics, or pathology of both chromosome 21 and chromosome 22 aneuploidies simultaneously.
4. Detailed Conceptual Explanation
To fully conceptualize autosomal trisomy of group G, one must examine the structural dynamics of human acrocentric chromosomes, the mechanics of gametogenesis, and the quantitative consequences of gene dosage imbalance. Group G autosomes are characterized by a centromere positioned exceptionally close to one end of the chromatid arms, yielding very short petite (p) arms composed largely of highly repetitive satellite DNA, ribosomal RNA genes (nucleolar organizer regions), and heterochromatin, alongside elongated long (q) arms that house the vast majority of protein-coding genes. When an extra Group G chromosome persists in the zygote, the physiological disturbance stems almost exclusively from the triplication of genes located on the q arm.
The biological pathology of Group G trisomy is driven by the "gene dosage hypothesis," which posits that a 150% dosage of structural proteins, transcription factors, signaling ligands, and non-coding regulatory RNAs disrupts stoichiometric balances in macromolecular assemblies and cellular biochemical pathways. On human chromosome 21 (HSA21), which spans roughly 47 million base pairs and contains over 200 protein-coding genes, this gene dosage disruption influences key developmental regulators. Among these are DYRK1A (a kinase involved in neurogenesis and brain development), SOD1 (superoxide dismutase 1, implicated in oxidative stress), APP (amyloid precursor protein, driving early-onset Alzheimer-type neurodegeneration), and RUNX1 (a master regulator of hematopoiesis). Overexpression of these genes cascades into impaired synaptic plasticity, altered mitochondrial function, immune system dysregulation, and cardiac cushion defects during embryogenesis.
When the aneuploidy involves chromosome 22—spanning approximately 51 million base pairs with a significantly higher gene density exceeding 500 protein-coding genes—the phenotypic disruption is substantially more profound. The triplication of critical embryogenic transcription factors and structural genes on 22q frequently causes catastrophic failure of gastrulation, cardiac septation, craniofacial development, and vascular morphogenesis. As a result, non-mosaic trisomy 22 usually results in spontaneous first-trimester embryonic demise. In rare surviving mosaic states, the gene dosage imbalance creates asymmetrical somatic anomalies, complex congenital heart defects, profound developmental delays, and severe dysmorphic features.
Beyond direct transcriptomic effects, Group G trisomy induces widespread epigenetic alterations throughout the entire nucleus. The presence of an extra chromosomal entity perturbs nuclear architecture, competing for limited transcriptomic machinery, splicing factors, and ribosomal machinery. This "genomic stress response" impairs universal cellular proliferation kinetics, activates baseline interferon pathways, alters DNA methylation landscapes, and triggers chronic endoplasmic reticulum stress, accounting for phenotypic traits shared across different chromosomal trisomies, such as intrauterine growth restriction and generalized cognitive vulnerability.
5. Historical Development
The historical trajectory of autosomal trisomy of group G is deeply intertwined with the birth of modern cytogenetics. In 1866, British physician John Langdon Down published the first systematic clinical description of the condition that would posthumously bear his name. For nearly a century, the underlying etiology remained an enigma, with hypotheses ranging from maternal exhaustion and endocrine failure to ancestral atavism and hidden infectious agents.
The breakthrough occurred in 1956 when Joe Hin Tjio and Albert Levan accurately established that the normal human somatic cell contains 46 chromosomes rather than 48. Shortly thereafter, in 1958–1959, the French physician-researchers Jérôme Lejeune, Marthe Gautier, and Raymond Turpin discovered that individuals with Down syndrome possessed 47 chromosomes, identifying a tiny extra acrocentric chromosome. This marked the absolute first time in medical history that an intellectual disability syndrome was conclusively linked to a specific numeric chromosomal aberration.
In April 1960, human cytogeneticists met at the University of Colorado to formulate the Denver Classification, establishing the canonical groups A through G based on unbanded chromosomal morphology. Because unbanded Giemsa staining made it impossible to visually discern the smaller acrocentric chromosome pairs from one another, the condition was formally categorized in literature as "trisomy of group G" or "G trisomy." During this era, clinical discussions often differentiated between "Group G1 trisomy" (Down syndrome) and the hypothetical or rare "Group G2 trisomy" (presumed trisomy 22).
The ambiguity was finally resolved in 1970 with the advent of quinacrine mustard fluorescent banding (Q-banding) by Torbjörn Caspersson and colleagues, followed rapidly by trypsin-Giemsa banding (G-banding). These banding techniques demonstrated that chromosome 21 and chromosome 22 displayed distinct light and dark heterochromatic patterns, confirming that the classical mongoloid phenotype was linked strictly to the smaller, less gene-dense chromosome 21, whereas the distinct, far more severe or embryonic-lethal malformations belonged to chromosome 22. Despite this molecular resolution, the historical classification "Group G trisomy" remains an essential conceptual framework in cytogenetic history, medical coding literature, and classic embryology texts.
6. Theoretical Foundations
The theoretical frameworks governing autosomal trisomy of group G span classic meiotic nondisjunction models, advanced maternal age theory, cohesin degradation hypotheses, and the downstream developmental instability theory. At the cellular level, the foundational premise centers on the mechanics of cell division during oogenesis and spermatogenesis.
In more than 90% of cases, Group G trisomy arises from maternal meiotic nondisjunction, primarily during Meiosis I (MI), with a smaller fraction occurring during Meiosis II (MII). The theoretical explanation for this phenomenon rests upon the "two-hit hypothesis" of human nondisjunction. The first hit occurs prenatally during maternal embryonic development, when oocytes arrest in prophase I (dictyotene stage) with aberrant or absent crossover patterns (chiasmata). Group G acrocentric chromosomes, due to their exceptionally short physical length, exhibit an increased susceptibility to achiasmate states or telomeric chiasmata, rendering homologous pairing intrinsically fragile. The second hit occurs decades later during oocyte maturation, wherein age-related depletion of cohesin complexes (such as REC8 and SMC1B) destabilizes sister chromatid cohesion, leading to premature separation of sister chromatids or failure of homologous pairs to segregate to opposing poles of the meiotic spindle apparatus.
Complementing this mechanical foundation is the "developmental instability theory" championed by geneticists such as Sewall Wright and amplified in trisomy studies by Charles Epstein. This theory posits that aneuploidy does not merely produce isolated discrete phenotypic defects through single-gene overexpressions; rather, it introduces generalized biological noise and transcriptomic instability. Because thousands of biochemical pathways operate near thresholds of equilibrium, the amplified transcript burden from a third Group G chromosome causes microenvironmental perturbations in protein folding, proteasome clearance, and cell cycle pacing, leading to generalized developmental delays, fluctuating asymmetry in bilateral anatomical structures, and cellular senescence.
7. Key Components, Types & Dimensions
Autosomal trisomy of group G manifests across multiple distinct biological dimensions, genetic etiologies, and clinical subclassifications:
- Primary (Free) Group G Trisomy: Caused by complete meiotic nondisjunction resulting in a non-disjunctional gamete that fertilizes a normal haploid gamete. Every somatic cell in the resulting organism contains 47 chromosomes (e.g., 47,XX,+21 or 47,XY,+22). This represents approximately 95% of all liveborn cases of chromosome 21 trisomy.
- Robertsonian Translocation Trisomy: A distinct structural cytogenetic mechanism occurring in approximately 3% to 4% of cases. The long arm of a Group G chromosome (most often 21q) fuses physically at the centromere with another acrocentric chromosome from Group D (e.g., chromosome 14) or Group G (another 21 or 22). Although the overall chromosome count remains 46, the individual possesses three functional copies of the Group G long arm, conferring an inherited risk if a parent carries a balanced translocation.
- Mosaic Group G Trisomy: Occurring in 1% to 2% of clinical presentations, mosaicism arises from post-zygotic mitotic nondisjunction or embryonic trisomic rescue. The affected individual develops two or more genetically distinct cell populations (e.g., 46,XX / 47,XX,+21). The severity of the clinical phenotype typically correlates with the percentage and tissue distribution of the trisomic cell line.
- Partial Group G Duplication: A rare structural variant wherein only a discrete segment of the long arm (e.g., 21q22, often termed the "Down syndrome critical region") is duplicated. These cases provide indispensable scientific value in mapping specific phenotypes to discrete genomic loci.
- Trisomy 22 Variants: Complete trisomy 22 is overwhelmingly lethal prior to 12 weeks of gestation. Liveborn presentations of Group G trisomy involving chromosome 22 are restricted almost exclusively to mosaic trisomy 22 or Emanuel syndrome (a partial trisomy 22 resulting from a 3:1 meiotic malsegregation of a maternal balanced t(11;22) translocation).
8. Examples & Illustrative Cases
To contextualize how autosomal trisomy of group G presents in clinical reality, consider the following representative clinical vignettes reflecting contrasting presentations across chromosome 21 and chromosome 22 involvement.
Case Illustration 1: Classic Free Trisomy 21 (Group G1 Trisomy). A female infant is born at 39 weeks of gestation to a 37-year-old mother. Physical examination reveals generalized hypotonia, a flat nasal bridge, upslanting palpebral fissures, prominent epicanthal folds, a single transverse palmar crease on both hands, and a widened space between the first and second toes (sandal gap). Echocardiography identifies an endocardial cushion defect (complete atrioventricular septal defect). Routine peripheral blood cytogenetic analysis confirms a karyotype of 47,XX,+21 resulting from maternal meiotic nondisjunction. Early therapeutic intervention, encompassing physical therapy, speech pathology, pediatric cardiology management, and thyroid screening, is initiated immediately, supporting long-term developmental milestones and social integration.
Case Illustration 2: Mosaic Group G Trisomy (Chromosome 22). A male infant is born with intrauterine growth restriction, asymmetrical hemihypoplasia of the left lower extremity, low-set malformed auricles with preauricular pits, micrognathia, and a persistent ductus arteriosus with an atrial septal defect. Standard neonatal peripheral blood karyotyping shows a normal 46,XY profile. However, persistent global developmental delay and linear cutaneous hypopigmentation following the lines of Blaschko prompt a full-thickness skin biopsy. Fibroblast cytogenetic testing reveals a mosaic karyotype: 80% normal 46,XY cells and 20% cells displaying 47,XY,+22. This demonstrates how somatic mosaicism for a Group G autosome can escape detection in standard leukocyte assays while producing profound organ-specific clinical sequelae.
9. Measurement & Assessment
The identification, measurement, and diagnostic confirmation of autosomal trisomy of group G have evolved from rudimentary staining methods to sophisticated high-throughput molecular diagnostics. Assessment occurs along two primary clinical tracks: prenatal screening and definitive diagnostic confirmation.
Prenatal screening begins in the first trimester (weeks 10 to 13) utilizing combined screening protocols that integrate maternal serum biomarkers (free beta-human chorionic gonadotropin [β-hCG] and pregnancy-associated plasma protein-A [PAPP-A]) with ultrasonographic measurement of fetal nuchal translucency (NT). In the modern era, cell-free fetal DNA (cfDNA) screening—frequently termed Non-Invasive Prenatal Testing (NIPT)—has transformed practice. By sequencing circulating cell-free trophoblastic DNA fragments present in maternal blood, cfDNA assays achieve detection rates exceeding 99% for trisomy 21 with false-positive rates below 0.1%, while also screening for trisomy 22 and other autosomal aneuploidies.
Definitive cytogenetic diagnosis requires obtaining fetal cells via invasive procedures such as chorionic villus sampling (CVS) at 10–13 weeks or amniocentesis at 15–20 weeks, or obtaining peripheral blood leukocytes postnatally. Confirmatory testing utilizes three primary diagnostic modalities:
- Standard G-Banded Karyotyping: Remains the clinical standard for establishing total chromosome count and resolving structural structural reorganizations such as Robertsonian translocations, which are vital for assessing parental recurrence risks.
- Fluorescence In Situ Hybridization (FISH): Employs fluorophore-labeled DNA probes specific to the loci of chromosome 21 (e.g., 21q22) or 22 (e.g., 22q11.2/22q13) on interphase and metaphase nuclei. FISH allows rapid, targeted verification of copy number variations within 24 to 48 hours.
- Chromosomal Microarray (CMA): Utilizing array comparative genomic hybridization (aCGH) or single nucleotide polymorphism (SNP) microarrays, CMA maps copy number variants across the genome with submicroscopic resolution, accurately determining the boundaries of partial Group G duplications and detecting low-level somatic mosaicism that may elude routine karyotyping.
10. Applications & Practical Significance
The clinical and operational significance of identifying autosomal trisomy of group G spans medical genetics, neonatal intensive care, community pediatrics, and public health policy. Accurate cytogenetic differentiation between chromosome 21 and chromosome 22 aneuploidies is paramount for establishing prognosis, managing immediate medical risks, and directing targeted surveillance throughout the lifespan.
In cases of confirmed trisomy 21, standardized clinical guidelines, such as those established by the American Academy of Pediatrics, delineate explicit lifelong surveillance programs. Newborns undergo mandatory echocardiography to identify congenital heart defects (present in approximately 40%–50% of cases), alongside evaluations for duodenal atresia and congenital cataracts. Longitudinal protocols mandate annual thyroid screening due to high autoimmune thyroiditis rates, regular audiometric evaluations for conductive and sensorineural hearing loss, ophthalmologic monitoring for refractive errors and keratoconus, and cervical spine radiographs between ages 3 and 5 to evaluate atlantoaxial instability prior to sports participation.
Furthermore, understanding the genetic status of a Group G trisomy informs parental reproductive counseling. While free trisomy 21 carries an empirical recurrence risk of roughly 1% (or age-related background risk, whichever is higher), a Robertsonian translocation involving maternal 14;21 carries a clinical recurrence risk of 10%–15%, and a maternal balanced 21;21 translocation results in a 100% recurrence risk of Down syndrome or monosomy 21 (lethal in utero). In the realm of public health and education, specialized developmental therapies (speech, occupational, and physical therapies) implemented during critical neurodevelopmental windows significantly maximize independent daily living skills and adaptive functionality.
11. Research & Empirical Evidence
Contemporary biomedical research into Group G trisomy centers on genomic editing, molecular pathobiology, and the identification of therapeutic targets to mitigate secondary cellular pathology. Transgenic murine models carrying human chromosome 21 syntenic regions—such as the Ts65Dn, Ts1Cje, and the highly faithful Dp(16)1Yey models—have yielded invaluable empirical data regarding neurodevelopmental mechanisms.
A critical body of research led by researchers such as Huntington Potter and David Holtzman confirmed that the APP gene located on 21q21.2 is directly responsible for universal Alzheimer disease neuropathology in individuals with Down syndrome by age 40. Longitudinal clinical trials have focused on small-molecule inhibitors targeting DYRK1A kinase activity to evaluate whether restoring normal phosphorylation states of nuclear factor of activated T-cells (NFAT) transcription factors can improve hippocampal-dependent learning and memory. Concurrently, Jeanne Lawrence and colleagues demonstrated proof-of-concept chromosomal silencing in vitro by inserting an XIST transgene into a single chromosome 21 in human pluripotent stem cells, successfully inducing heterochromatinization and systemic transcriptional repression of the supernumerary autosome.
In oncology, extensive research explores the enigmatic dual nature of Group G trisomy: children with trisomy 21 possess a 10- to 20-fold increased risk of acute lymphoblastic leukemia (ALL) and acute megakaryoblastic leukemia (AMKL), frequently driven by acquired mutations in GATA1. Strikingly, adults with Down syndrome display a remarkably reduced incidence of solid tumors (such as breast, lung, and prostate carcinomas). Research indicates that triplication of endogenous angiogenesis inhibitors, including RCAN1 and ADAMTS1 located on chromosome 21, provides a potent protective anti-angiogenic environment against solid tumor vascularization.
12. Cultural & Cross-Cultural Considerations
The societal, cultural, and ethical frameworks surrounding autosomal trisomy of group G vary dramatically across geographic regions, socioeconomic backgrounds, and legal jurisdictions. The historical moniker "Mongolism," introduced by John Langdon Down due to perceived facial resemblance to individuals of East Asian ancestry, reflected 19th-century racial classification frameworks. In 1965, following direct appeals from Mongolian delegates to the World Health Organization, the term was officially expunged in favor of Down syndrome, marking a pivotal transition away from racially biased medical terminology.
In contemporary society, the widespread integration of first-trimester prenatal screening and cell-free DNA technologies has led to profound demographic shifts in birth rates of infants with trisomy 21. In several northern European nations, widespread state-supported prenatal screening coupled with permissive termination legislation has resulted in termination rates exceeding 90%–95% following a confirmed prenatal diagnosis of Down syndrome. Conversely, in regions influenced by strong religious doctrines, restrictive legal structures, or cultural frameworks emphasizing absolute sanctity of life, termination rates are vastly lower, resulting in higher live-birth prevalence.
Furthermore, the cultural perception of disability has undergone a profound paradigm shift over the past half-century. The transition from institutionalization toward full community inclusion, supported employment, and self-advocacy movements has revealed that individuals with Group G trisomy achieve substantially higher levels of social participation, emotional intelligence, and cognitive development than was historically deemed possible under institutional confinement.
13. Criticisms, Debates & Limitations
Despite deep scientific understanding, the classification, diagnostics, and management of Group G autosomal trisomy remain subject to intense clinical and ethical debates. A prominent biological debate involves the concept of the "Down Syndrome Critical Region" (DSCR) on 21q22. For decades, prevailing cytogenetic dogma posited that a microscopic 1.6-to-2.5 megabase region was solely responsible for the vast majority of the classic Down syndrome phenotype. However, modern whole-genome sequencing and refined human partial trisomy registries have largely overturned this deterministic model, showing that classic features like congenital heart disease require complex interactions across multiple non-contiguous regions of the chromosome.
Ethical dilemmas surrounding prenatal screening represent another contentious arena. Disability rights advocates argue that marketing cell-free DNA testing as routine maternal wellness care implicitly frames conditions such as Down syndrome as medical errors to be prevented or eliminated, thereby devaluing the lives of neurodivergent and disabled individuals. Clinicians face challenges regarding the delivery of unbiased, comprehensive balanced counseling, ensuring that prospective parents receive realistic information covering both medical comorbidities and modern social achievements rather than outdated clinical prognoses.
A major diagnostic limitation in classic cytogenetic classifications like "Group G trisomy" is the inability of routine G-banding to resolve microduplications, structural rearrangements, or cryptic mosaicism. In cases of low-grade mosaic trisomy 22 or mosaic trisomy 21, somatic lineages may be absent in peripheral blood yet present in cardiac or neural tissue, leading to misleading clinical prognoses based solely on standard blood karyotypes.
14. Related Terms & Distinctions
To avoid diagnostic ambiguity and understand human karyotypic anomalies, autosomal trisomy of group G must be distinguished from several related chromosomal constructs:
- Trisomy 21 vs. Trisomy 22: While both are Group G autosomes, Trisomy 21 constitutes Down syndrome, compatible with decades of postnatal life. Trisomy 22 represents a distinct clinical entity that is almost uniformly lethal in early gestation, surviving only in mosaic forms characterized by microcephaly, profound growth failure, and severe structural urogenital and cardiac malformations.
- Group D Trisomy: Encompasses trisomies of medium-sized acrocentric chromosomes (pairs 13, 14, and 15), most notably Trisomy 13 (Patau syndrome), which is characterized by holoprosencephaly, microphthalmia, cleft lip/palate, and polydactyly, presenting a radically worse immediate postnatal prognosis than Group G trisomy.
- Group E Trisomy: Refers to trisomies of short submetacentric autosomes (pairs 16, 17, and 18), primarily Trisomy 18 (Edwards syndrome). Edwards syndrome features prominent occiput, clenched hands with overlapping fingers, rocker-bottom feet, and high infant mortality, distinctly differentiated from Group G dysmorphology.
- Cat Eye Syndrome (Schmid-Fraccaro Syndrome): Caused by an inverted duplicated marker chromosome derived from chromosome 22 (partial tetrasomy of 22pter-22q11). Although involving a Group G autosome, it involves a fourfold dosage of select 22p-q loci rather than a whole-chromosome trisomy, presenting with coloboma of the iris and anal atresia.
- Emanuel Syndrome (Supernumerary der(22)t(11;22) Syndrome): A partial trisomy characterized by the presence of an extra derivative chromosome composed of parts of chromosome 11 and 22, yielding partial trisomy of 11q and 22q rather than a complete primary Group G trisomy.
15. Summary / Key Takeaways
Autosomal trisomy of group G is a foundational category in medical cytogenetics, referring to the presence of an extra small acrocentric chromosome from pairs 21 or 22. Predominantly manifested as trisomy 21 (Down syndrome), it stands as the most common viable autosomal aneuploidy in humans, leading to characteristic phenotypic facial features, generalized hypotonia, neurodevelopmental delays, specific patterns of congenital organ malformations, and elevated risks for early-onset Alzheimer pathology and childhood leukemias. While full trisomy 22 is generally incompatible with embryonic survival, mosaic forms and structural variants illustrate the severe consequences of gene-dense aneuploidy.
The transition from unbanded cytogenetic labels to high-resolution fluorescent and molecular karyotyping has clarified the precise gene dosage dynamics underlying this condition. Advanced prenatal screening technologies, comprehensive multidisciplinary clinical intervention protocols, and emerging molecular therapeutics targeting gene over-expression continue to redefine outcomes and enhance the quality of life for individuals living with this genomic alteration.
References
- Down, J. L. (1866). Observations on an ethnic classification of idiots. Clinical Lectures and Reports, London Hospital, 3, 259–262.
- Epstein, C. J. (2001). The consequences of chromosome imbalance. American Journal of Medical Genetics, 106(2), 159–176. https://doi.org/10.1002/ajmg.1396
- Hassold, T., & Hunt, P. (2001). To err (meiotically) is human: The genesis of human aneuploidy. Nature Reviews Genetics, 2(4), 280–291. https://doi.org/10.1038/35066065
- Lejeune, J., Gautier, M., & Turpin, R. (1959). Étude des chromosomes somatiques de neuf enfants mongoliens [Study of somatic chromosomes in nine mongoloid children]. Comptes Rendus Hebdomadaires des Séances de l’Académie des Sciences, 248(11), 1721–1722.
- Roper, R. J., & Reeves, R. H. (2006). Understanding the basis for Down syndrome phenotypes. PLOS Genetics, 2(3), e50. https://doi.org/10.1371/journal.pgen.0020050